Does Humana Cover Wegovy or Ozempic for Weight Loss in 2026?

Direct answer (40-60 words)

Humana coverage of Wegovy and Ozempic for weight loss depends on plan type. Most Humana Medicare Advantage plans don't cover Wegovy for weight loss alone, though some now cover it for cardiovascular risk reduction. Employer-sponsored plans vary widely. Ozempic is typically only covered when prescribed for type 2 diabetes, not for off-label weight loss.

Table of contents

1. The 30-second answer
2. How Humana sorts GLP-1 medications across its plans
3. Medicare Advantage and Part D rules in 2026
4. Employer-sponsored Humana plans
5. Individual and marketplace coverage
6. Prior authorization requirements that actually get approved
7. The 2024 cardiovascular pathway for Wegovy
8. What to do if Humana denies your prescription
9. Out-of-pocket costs without coverage
10. The compounded semaglutide alternative
11. FAQ
12. Footer disclaimers

How Humana sorts GLP-1 medications across its plans

Humana doesn't have a single "weight loss policy." It has three main coverage categories with different rules.

Medicare Advantage and Part D plans. These follow federal Medicare rules with Humana-specific formulary choices on top.

Employer-sponsored group plans. These follow whatever benefit structure the employer has negotiated. The same drug can be fully covered, partially covered, or excluded depending on which employer's plan you're on.

Individual and ACA marketplace plans. These are governed by state and federal marketplace rules, with Humana's own formulary applied.

Within each category, Wegovy, Ozempic, and Zepbound are treated differently because of their FDA-approved indications.

• Ozempic is FDA-approved for type 2 diabetes, not weight loss. Humana plans generally cover it for diabetes when criteria are met, and almost universally deny it for off-label weight loss use.
• Wegovy is FDA-approved for chronic weight management in adults with BMI over 30 (or 27 with comorbidities), and as of 2024 also for cardiovascular risk reduction in adults with established cardiovascular disease. Coverage depends on indication.
• Zepbound is FDA-approved for chronic weight management. Coverage rules track Wegovy's, with similar prior authorization expectations.

The most common pattern: a Humana plan that covers Wegovy for cardiovascular indication but not for weight loss alone. A patient with cardiovascular disease and obesity may qualify under the cardiovascular pathway when they wouldn't qualify for weight-loss-only.

Medicare Advantage and Part D rules in 2026

Federal Medicare law has historically excluded weight loss medications from Part D coverage. The Inflation Reduction Act of 2022 didn't change that exclusion, but the FDA's 2024 expansion of Wegovy's label to include cardiovascular risk reduction created a workaround.

As of 2026, here's what most Humana Medicare Advantage and Part D plans cover:

For Wegovy:

• Covered for adults with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) plus a BMI over 27, when prescribed for cardiovascular event reduction
• Generally NOT covered for weight loss alone, regardless of BMI
• Prior authorization required even for the cardiovascular indication

For Ozempic:

• Covered for adults with type 2 diabetes meeting plan criteria (HbA1c, comorbid conditions, prior medication trials)
• NOT covered when prescribed off-label for weight loss
• Prior authorization typically required

For Zepbound:

• Coverage on Humana Medicare plans is limited as of 2026
• A small number of plans now include Zepbound on formulary for cardiovascular or sleep apnea indications
• Most plans still exclude it for weight loss alone

Patients with Medicare Part D facing a denial sometimes find that switching to a different Part D plan during open enrollment opens up better coverage. Humana's specific plan selection in your county varies year to year.

Employer-sponsored Humana plans

Employer plans are the most variable. The decision to include or exclude GLP-1 weight-loss medications is made by the employer, not by Humana directly. Some employers cover everything. Some cover nothing. Most fall somewhere in between.

The drivers of employer coverage decisions:

• Cost. A typical large employer adding Wegovy coverage to its formulary sees pharmacy benefit costs rise 5 to 15%, depending on workforce demographics. Some employers absorb the cost, others don't.
• Workforce health. Employers with high obesity rates and high diabetes rates often see better long-term cost outcomes from GLP-1 coverage and choose to cover. Others don't.
• Plan design. PPO plans typically have broader formularies than HMO or EPO plans on the same employer.
• Renewal cycle. Employers renegotiate benefits annually. Coverage that's denied this year may be added next year, or vice versa.

How to check your specific plan:

• Log in to your Humana member portal
• Look for the formulary or "drug list" section
• Search for "Wegovy" and "Ozempic" specifically (not "semaglutide")
• Note the tier and any prior authorization or step therapy requirements
• Or call the member services number on the back of your card

The formulary listing is the truth. A general "Humana covers Wegovy" answer doesn't apply to employer plans. Your specific employer's plan controls.

Individual and marketplace coverage

ACA marketplace plans through Humana follow state and federal essential health benefit rules. Weight loss medications are not federally required as essential health benefits.

In practice, marketplace plans usually:

• Cover Ozempic for type 2 diabetes (often with prior authorization and step therapy)
• Exclude Wegovy and Zepbound for weight loss
• Cover bariatric surgery in some states (separate from medication coverage)

A handful of states (like North Dakota, California for some plans) have stricter requirements that include weight loss coverage. Most don't.

If you have a marketplace silver or gold plan and your provider prescribes Wegovy for weight loss, expect a denial. The prior authorization and appeal pathway exists but rarely succeeds for weight-loss-only indications on individual marketplace plans.

Prior authorization requirements that actually get approved

When a Humana plan does cover a GLP-1 for an indication, prior authorization is almost always required. Approval depends on documentation matching the plan's criteria. The criteria vary by plan, but common requirements include:

For Wegovy (weight management):

• BMI of 30 or higher, OR BMI of 27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Documented prior weight loss attempts (often 6 months of supervised diet and exercise, or failure with phentermine or another older weight loss medication)
• Provider attestation of appropriate use
• Sometimes: enrollment in a weight management program

For Wegovy (cardiovascular indication):

• Established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• BMI over 27
• Provider documentation of cardiovascular risk reduction goals

For Ozempic (type 2 diabetes):

• Diagnosed type 2 diabetes
• HbA1c above plan threshold (often 7.0%, sometimes 6.5%)
• Step therapy: documented failure or intolerance of metformin (the first-line type 2 diabetes drug)
• Sometimes: failure of a second oral agent before approval of injectable

The provider's office handles the prior authorization paperwork. Patients can speed it up by ensuring the records reflect the documentation requirements (BMI in chart notes, prior medication trials documented, comorbidity ICD-10 codes correctly listed).

The 2024 cardiovascular pathway for Wegovy

In March 2024 the FDA expanded Wegovy's label to include reduction of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and obesity or overweight. This was based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which followed 17,604 patients for over 3 years.

Why this matters for Humana coverage: the cardiovascular indication is not a weight loss indication. Medicare can cover it without violating the weight-loss exclusion.

To qualify for the cardiovascular pathway, a patient typically needs:

• Documented history of MI, stroke, or peripheral artery disease (ICD-10 codes for these conditions in the chart)
• BMI over 27
• A prescription specifically for cardiovascular risk reduction (the prescription wording or accompanying diagnosis matters)

This pathway has opened coverage for thousands of patients who previously couldn't get Wegovy through Humana Medicare plans. It hasn't opened coverage for patients without cardiovascular disease who have obesity alone.

A patient with type 2 diabetes plus obesity but without prior cardiovascular events may still struggle to get Wegovy coverage; the Ozempic-for-diabetes pathway is usually the better route in that scenario.

What to do if Humana denies your prescription

A denial isn't the end. The appeal process recovers a meaningful percentage of denied prescriptions, particularly those denied for documentation reasons rather than fundamental coverage exclusions.

Step 1: Read the denial letter. Identify the specific reason for denial. The most common categories are:

• Plan exclusion (the medication isn't covered for any indication on this plan)
• Step therapy not met (need to try another drug first)
• Prior authorization missing or incomplete
• Diagnosis not consistent with covered indications
• Quantity limits exceeded

Step 2: Address the specific reason. For plan exclusions, the appeal rarely succeeds; consider plan switching at next open enrollment. For step therapy, document that you've tried (or can't tolerate) the required prior medications. For prior authorization issues, provide the missing documentation through your provider. For diagnosis issues, check whether the prescription was correctly coded; sometimes a re-prescription with the right ICD-10 codes resolves it.

Step 3: Submit the appeal. Humana provides instructions in the denial letter. Appeals typically include:

• A letter from the prescribing provider explaining medical necessity
• Supporting clinical records (BMI history, prior medication trials, lab results)
• Documentation of failed alternatives if step therapy applies
• Member's own statement when appropriate

Step 4: Escalate if needed. If the first internal appeal fails, you can request a second internal review and then an external review by an independent organization. Medicare members have additional federal review rights through CMS.

Step 5: Consider alternatives. While the appeal is pending, options include:

• The Novo Nordisk patient assistance program for income-eligible patients
• Manufacturer savings cards (limited to commercially insured patients, not Medicare)
• Compounded semaglutide as a cash-pay option (see below)

Out-of-pocket costs without coverage

If Humana doesn't cover your medication and the appeal route doesn't open coverage, the cash market is where most patients end up.

Brand-name pricing in 2026:

• Wegovy list price: $1,349/month (cash)
• Ozempic list price: $1,069/month (cash)
• Zepbound list price: $1,069/month (cash)
• Manufacturer savings cards: reduce eligible commercial-insurance copays to $25 to $200/month, but only for patients with commercial insurance, not Medicare

For the broader cost picture on Ozempic at retail pharmacies, see related guide.

Manufacturer patient assistance programs: Novo Nordisk and Eli Lilly both offer patient assistance for low-income, uninsured patients. Income limits typically apply. Application is through the manufacturer's website.

The compounded semaglutide alternative

For patients who can't get Humana coverage and can't afford brand-name list prices, compounded semaglutide is a cash option. Compounded medications use the same active ingredient prepared by a state-licensed compounding pharmacy in response to an individual prescription.

Pricing context:

• Brand-name semaglutide (Wegovy): $1,349/month list
• Compounded semaglutide through a telehealth platform like FormBlends: typically much lower
• Insurance: not covered by Humana or other carriers; cash-pay only

Important caveats:

• Compounded medications are not FDA-approved
• They are not interchangeable with Wegovy or Ozempic
• They have not undergone the same review process as brand-name drugs
• Quality depends on the compounding pharmacy

For more on the cost and value tradeoffs, see related guide.

Compounded options work for some patients and not for others. The decision depends on insurance status, financial situation, and provider guidance.

FAQ

Does Humana cover Wegovy for weight loss?

Most Humana plans don't cover Wegovy for weight loss alone. Some now cover it under the cardiovascular indication added to the FDA label in 2024 for patients with established cardiovascular disease. Employer-sponsored plans vary widely.

Does Humana Medicare cover Ozempic?

Yes, for type 2 diabetes when plan criteria are met (often including a step therapy requirement to try metformin first). Humana Medicare does not cover Ozempic for off-label weight loss use.

What about Humana coverage for Zepbound?

Limited as of 2026. A small number of Humana plans cover Zepbound for cardiovascular or sleep apnea indications. Most plans exclude it for weight loss alone.

What's the prior authorization process for Wegovy on Humana?

The provider submits a PA request with documentation of BMI, prior weight loss attempts, comorbid conditions, and (where applicable) cardiovascular history. Approval depends on whether the documentation matches the plan's specific criteria.

Does Humana cover compounded semaglutide?

No. Humana, like other major insurers, does not cover compounded GLP-1 medications. These are typically cash-pay through a telehealth platform.

My Humana plan denied my Wegovy prescription. What do I do?

Read the denial letter to identify the reason. Common reasons include plan exclusion, step therapy not met, missing prior authorization, or diagnosis mismatch. Appeals through Humana's process can succeed for documentation-related denials.

Can I get Ozempic for weight loss if I have prediabetes?

Probably not through Humana coverage. Ozempic is FDA-approved for type 2 diabetes, not prediabetes or weight loss. Plans typically deny prescriptions written for off-label use.

What if my employer plan through Humana doesn't cover Wegovy?

Talk with your employer's HR or benefits team about whether GLP-1 coverage is being considered for the next plan year. Some employers add coverage when employees express demand.

Does Humana require step therapy for GLP-1 medications?

Often yes. For diabetes, a typical requirement is documented failure or intolerance of metformin. For weight loss (where covered), some plans require failure of older weight loss agents like phentermine.

How do I find out exactly what my Humana plan covers?

Log in to the member portal and check the formulary, or call the number on the back of your card. The general "Humana covers X" answer doesn't apply uniformly to all plans.

Can I appeal a Humana denial?

Yes. Humana has an internal appeal process, followed by external independent review if internal appeals fail. Medicare members have additional federal review rights.

Is the manufacturer savings card available for Humana members?

Novo Nordisk and Eli Lilly savings cards are typically restricted to commercially insured patients. Medicare members (including Humana Medicare Advantage) usually can't use them due to federal anti-kickback rules.

Author / review note

Reviewed by the FormBlends Medical Team. References include the SELECT trial publication (Lincoff et al., New England Journal of Medicine, 2023), the FDA-approved labels for Wegovy, Ozempic, and Zepbound, the Inflation Reduction Act provisions on Medicare drug coverage, and Humana's published 2026 plan formularies.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Humana is a registered trademark of Humana Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.